Jeremy Warner summarizes the paper published in Lancet describing the outcome of cancer patients with COVID-19. Drs. Marina Garassino and Leora Horn discuss their AACR study of COVID-19 in lung cancer. Dr. Kaushik Amancherla and Dr. Javid Moslehi discuss the link between COVID-19 and cardiovascular disease. The Uromigos struggle to describe what cancer care looks like in three months’ time during the COVID-19 pandemic. The Uromigos debate—and can’t agree on—how to approach COVID-infected GU cancer patients who need systematic treatment. Dena Battle presents a 500-patient survey on issues around COVID-19 and kidney cancer treatment. Dr. Toni Choueiri joins The Uromigos to discuss the evolving landscape of the COVID-19 pandemic in Boston. Dr. Nick Mark, professor and pulmonary critical care internist in Seattle, discusses the latest data on drug treatments and ... The Uromigos discuss the practicalities in surgery for bladder cancer in the era of COVID-19 with Dr. Betsy Plimack. Dr. Brian Rini and Dr. Tom Powles discuss the data and ongoing studies with the IL-6 antibody tocilizumab with Dr. Nick Mark. Dr. David Boulware discusses existing data and ongoing prophylaxis studies on hydroxychloroquinine for COVID-19. The Uromigos speak with Drs. Petros Grivas and Steven Pergam from the Fred Hutchinson Cancer Center during a COVID-19 spike. Dr. Chuck Drake and Dr. Doug Johnson discuss possible risk-benefits of immune checkpoint inhibitors during the COVID-19 ... Dena Battle, President of KCCure, answers patient-focused questions about kidney cancer management during the pandemic. The Uromigos and their colleagues discuss how the COVID-19 pandemic is affecting cancer patients around the world. Dr. Ronan Breen, a respiratory physician in London, discusses the coronavirus and how it is changing cancer care.